Misregulation of PPAR Functioning and Its Pathogenic Consequences Associated with Nonalcoholic Fatty Liver Disease in...

Area of Science:

• Metabolic disorders
• Hepatology
• Nutritional science

Background:

• Nonalcoholic fatty liver disease (NAFLD) in obesity is driven by complex pathogenic mechanisms, including PPAR signaling dysregulation.
• Downregulation of liver PPAR-α, coupled with increased PPAR-γ and SREBP-1c, disrupts the balance between lipogenesis and fatty acid oxidation, promoting steatosis.
• Obesity-induced oxidative stress, LCPUFA n-3 depletion, insulin resistance, hypoadiponectinemia, and ER stress contribute to NAFLD pathogenesis.

Purpose of the Study:

• To evaluate LCPUFA n-3 supplementation as a therapeutic strategy for NAFLD in obesity.
• To investigate the impact of LCPUFA n-3 on liver steatosis and inflammatory pathways.

Main Methods:

• The study focuses on the molecular mechanisms of NAFLD, particularly PPAR signaling pathways.
• It reviews existing antisteatotic strategies targeting PPAR-α, such as fibrates and thiazolidinediones, and their limitations.
• The potential of LCPUFA n-3 supplementation is examined based on its effects on liver steatosis and inflammation.

Main Results:

• LCPUFA n-3 supplementation significantly reduces liver steatosis scores.
• It also demonstrates a positive anti-inflammatory outcome.
• PPAR-α downregulation and LCPUFA n-3 depletion may enhance the binding of pro-inflammatory factors NF-κB and AP-1.

Conclusions:

• LCPUFA n-3 supplementation emerges as a promising therapeutic alternative for NAFLD in obesity, addressing both steatosis and inflammation.
• Restoring LCPUFA n-3 levels may counteract the pro-inflammatory signaling implicated in the progression from steatosis to steatohepatitis.